Helen Heslop, MD

Adjunct Professor of Medicine, Institute for Academic Medicine
Full Affiliate Member, Research Institute
Houston Methodist


Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 1991. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Areas Of Expertise

Cancer Adoptive immunotherapy Effector cells Hemopoietic stem cell transplantation

Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation
Tzannou, I, Papadopoulou, A, Naik, S, Leung, K, Martinez, CA, Ramos, CA, Carrum, G, Sasa, G, Lulla, P, Watanabe, A, Kuvalekar, M, Gee, AP, Wu, MF, Liu, H, Grilley, BJ, Krance, RA, Gottschalk, S, Brenner, MK, Rooney, CM, Heslop, HE, Leen, AM & Omer, B 2017, Journal of Clinical Oncology, vol 35, no. 31, pp. 3547-3557. DOI: 10.1200/JCO.2017.73.0655

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Ramos, CA, Ballard, B, Zhang, H, Dakhova, O, Gee, AP, Mei, Z, Bilgi, M, Wu, MF, Liu, H, Grilley, B, Bollard, CM, Chang, BH, Rooney, CM, Brenner, MK, Heslop, HE, Dotti, G & Savoldo, B 2017, Journal of Clinical Investigation, vol 127, no. 9, pp. 3462-3471. DOI: 10.1172/JCI94306

Equal opportunity CAR T cells
Rouce, RH & Heslop, HE 2017, Blood, vol 129, no. 25, pp. 3275-3277. DOI: 10.1182/blood-2017-04-779983

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Heczey, A, Louis, CU, Savoldo, B, Dakhova, O, Durett, A, Grilley, B, Liu, H, Wu, MF, Mei, Z, Gee, A, Mehta, B, Zhang, H, Mahmood, N, Tashiro, H, Heslop, HE, Dotti, G, Rooney, CM & Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.05.012

Exhausting alloreactivity of donor-derived CAR T cells
Mamonkin, M & Heslop, HE 2017, Nature Medicine, vol 23, no. 2, pp. 147-148. DOI: 10.1038/nm.4276

Fall of the mutants: T cells targeting BCR-ABL
Lulla, P & Heslop, HE 2017, Blood, vol 129, no. 5, pp. 539-540. DOI: 10.1182/blood-2016-12-757336

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Mohammed, S, Sukumaran, S, Bajgain, P, Watanabe, N, Heslop, HE, Rooney, CM, Brenner, MK, Fisher, WE, Leen, AM & Vera, JF 2017, Molecular Therapy, vol 25, no. 1, pp. 249-258. DOI: 10.1016/j.ymthe.2016.10.016

Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N, Bajgain, P, Sukumaran, S, Ansari, S, Heslop, HE, Rooney, CM, Brenner, MK, Leen, AM & Vera, JF 2016, OncoImmunology, vol 5, no. 12, e1253656. DOI: 10.1080/2162402X.2016.1253656

Clinical responses with T lymphocytes targeting malignancy-associated ? light chains
Ramos, CA, Savoldo, B, Torrano, V, Ballard, B, Zhang, H, Dakhova, O, Liu, E, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Brenner, MK, Heslop, H & Dotti, G 2016, Journal of Clinical Investigation, vol 126, no. 7, pp. 2588-2596. DOI: 10.1172/JCI86000

T cells for viral infections after allogeneic hematopoietic stem cell transplant
Bollard, CM & Heslop, HE 2016, Blood, vol 127, no. 26, pp. 3331-3340. DOI: 10.1182/blood-2016-01-628982

Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines
Daley, GQ, Hyun, I, Apperley, JF, Barker, RA, Benvenisty, N, Bredenoord, AL, Breuer, CK, Caulfield, T, Cedars, MI, Frey-Vasconcells, J, Heslop, HE, Jin, Y, Lee, RT, McCabe, C, Munsie, M, Murry, CE, Piantadosi, S, Rao, M, Rooke, HM, Sipp, D, Studer, L, Sugarman, J, Takahashi, M, Zimmerman, M & Kimmelman, J 2016, Stem Cell Reports, vol 6, no. 6, pp. 787-797. DOI: 10.1016/j.stemcr.2016.05.001

Forecasting cytokine storms with new predictive biomarkers
Rouce, RH & Heslop, HE 2016, Cancer Discovery, vol 6, no. 6, pp. 579-580. DOI: 10.1158/2159-8290.CD-16-0493

New ISSCR guidelines: Clinical translation of stem cell research
Kimmelman, J, Heslop, HE, Sugarman, J, Studer, L, Benvenisty, N, Caulfield, T, Hyun, I, Murry, CE, Sipp, D & Daley, GQ 2016, The Lancet, vol 387, no. 10032, pp. 1979-1981. DOI: 10.1016/S0140-6736(16)30390-7

Policy: Global standards for stem-cell research
Kimmelman, J, Hyun, I, Benvenisty, N, Caulfield, T, Heslop, HE, Murry, CE, Sipp, D, Studer, L, Sugarman, J & Daley, GQ 2016, Nature, vol 533, pp. 311-313. DOI: 10.1038/533311a

CAR-T cell therapy for lymphoma
Ramos, CA, Heslop, HE & Brenner, MK 2016, Annual Review of Medicine, vol 67, pp. 165-183. DOI: 10.1146/annurev-med-051914-021702

Erratum: CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo (Science Translational Medicine (2016) 8:321 (321er1))
Hanley, PJ, Melenhorst, JJ, Nikiforow, S, Scheinberg, P, Blaney, JW, Demmler-Harrison, G, Cruz, CR, Lam, S, Krance, RA, Leung, KS, Martinez, CA, Liu, H, Douek, DC, Heslop, HE, Rooney, CM, Shpall, EJ, Barrett, AJ, Rodgers, JR & Bollard, CM 2016, Science Translational Medicine, vol 8, no. 321, 321er1. DOI: 10.1126/scitranslmed.aaf1718

Recent advances in T-cell immunotherapy for haematological malignancies
Rouce, RH, Sharma, S, Huynh, M & Heslop, HE 2016, British Journal of Haematology. DOI: 10.1111/bjh.14470

Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation
Bollard, CM & Heslop, HE 2016, . in Thomas Hematopoietic Cell Transplantation: Fifth Edition. vol. 2-2, Wiley-Blackwell, pp. 816-827. DOI: 10.1002/9781118416426.ch68

Checkpoint inhibition and cellular immunotherapy in Lymphoma
Lulla, P & Heslop, HE 2016, Hematology, vol 2016, no. 1, pp. 390-396. DOI: 10.1182/asheducation-2016.1.390

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch
Chang, EC, Liu, H, West, JA, Zhou, X, Dakhova, O, Wheeler, DA, Heslop, HE, Brenner, MK & Dotti, G 2015, Molecular Therapy. DOI: 10.1038/mt.2015.217